NCT00981240已完成1 期
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Incidence of DLTs during the initial 4-week period of treatment
研究概览
简要总结
Primary objectives:
- To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose limiting toxicities (DLTs) in the proposed dose regimen
- To evaluate the pharmacokinetic (PK) profile of SAR103168
Secondary objectives:
- To characterize the global safety profile of SAR103168
- To evaluate preliminary anti-leukemia activity
- To investigate the potential induction effect on CYP3A4 and persistence of this effect by using oral midazolam as a probe substrate in patients enrolled into the expanded cohort at the MTD
- To determine the metabolic pathways of SAR103168 and identify the chemical structures of metabolites
- To determine the potential impact of SAR103168 on the QTc interval in patients enrolled at the MTD
详细描述
Patients will receive the study drug until unacceptable toxicity, clinically significant disease progression, withdrawal of consent or investigator's decision, and for a maximum of 1 year.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes with no curative option available including any of the following:
- •Patients with de novo or secondary acute myelogenous leukemia (AML) (except acute promyelocytic leukemia), meeting one of the following conditions:
- •Refractory or relapsed AML; In case of first relapse the CR duration should be less than 12 months. If the relapse failed at least one prior salvage attempt, the CR duration may be more than 12 months.
- •Into the expanded cohort at the MTD, previously untreated AML patients over age 60 with poor- risk cytogenetics who are not eligible for or do not accept induction chemotherapy may also be included.
- •Patients with refractory/relapsed acute lymphoblastic leukemia (ALL)
- •Patients with high-risk myelodysplastic syndrome (MDS) as defined by the International Prognostic Scoring System
- •Patients with chronic myeloid leukemia in blast phase (CML-BP)
排除标准
- •performance status > 2
- •Active uncontrolled central nervous system leukemia
- •Cytotoxic therapy within 2 weeks prior to the first dose of SAR
- •For the non cytotoxic agents/investigational drugs this washout period should be at least 2 weeks or at least 5 half-lives whichever is longer. Hydroxyurea must be stopped at least 24 hours prior to the first dose of SAR103168
- •Lack of recovery from toxicities from prior therapies to grade < 1
- •White blood cells > 30 x 10^9/L prior to the first dose of SAR103168
- •Prior allogeneic stem cell transplantation or donor lymphocytes infusion within 3 months preceding the first dose of SAR103168
- •Any of the following within 6 months prior to the first dose of SAR103168:
- •Myocardial infarction, congestive heart failure, documented angina pectoris, arrhythmia requiring medication (in particular atrial fibrillation or flutter), severe conduction disorder (second or third atrio-ventricular block, pacemaker), coronary/peripheral artery bypass graft surgery
- •Arterial or venous thromboembolism, deep venous thrombosis
- •Left ventricular ejection fraction < 50% by echocardiography or multiple gated acquisition scan
- •Cardiac ischemia on 12-lead ECG
- •Baseline QTc-interval > 500 msec
- •Hypertension uncontrolled with appropriate therapy
- •Active infection (viral, bacterial or fungal) uncontrolled with appropriate therapy
- •Major surgery within 6 weeks prior to the first dose of SAR103168
- •Poor organ function defined by one of the following:
- •Total bilirubin > 1.5 x upper limit of normal (ULN) unless related to leukemia (i.e. hemolysis) or Gilbert's syndrome
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2.5 x ULN
- •Serum creatinine > 1.5 x ULN or calculated creatinine clearance < 50 mL/min
- •Patients under treatment with potent inhibitors of CYP3A4 unless these treatments may be stopped at least 3 days prior to the first dose of SAR103168
- •Patients under treatment with CYP3A4 or CYP2C9 inducers, unless these treatments may be stopped at least 3 days prior to the first dose of SAR103168
- •Pregnant or breast-feeding women or refusal to use adequate contraceptive method, when applicable.
研究组 & 干预措施
Dose escalation
Experimental
Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
干预措施: SAR103168 (Drug)
结局指标
主要结局
Incidence of DLTs during the initial 4-week period of treatment
时间窗: 4 weeks
Pharmacokinetic parameters of SAR103168
时间窗: First course: Days 1, 2, 5, 6, and 8; Second and subsequent courses: Day 5 only
次要结局
- Global safety profile of SAR103168 based on treatment emergent adverse events (TEAEs), serious adverse events (SAEs), deaths, laboratory abnormalities(Treatment period up to 1 year)
- Preliminary evidence of anti-leukemia activity(Treatment period up to 1 year)
- Pharmacokinetic parameters of midazolam in the absence and the presence of SAR103168.(During second (Day-1 and Day 5) and forth course (Day 5))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid TumorsMalignant Solid TumorsNCT01391533Sanofi72
已完成
1 期
SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's LymphomaNon-HodgkinLymphomaNCT00796731Sanofi77
已完成
1 期
Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor PatientsNeoplasm MalignantNCT01657214Sanofi70
已完成
1 期
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid TumorNeoplasm MalignantNCT01156870Sanofi114
已完成
1 期
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT01512758Millennium Pharmaceuticals, Inc.36